Evidence map›Paper›PMID 33898301›Full record

ArticleFrontiers in oncology2020

The Clinical Implications of Tumor Mutational Burden in Osteosarcoma.

Lu Xie, Yufei Yang, Wei Guo, Dongxue Che, Jie Xu, Xin Sun, Kuisheng Liu, Tingting Ren, Xingyu Liu, Yi Yang and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Whole-Exome Analysis and Osteosarcoma: A Game Still Open.International journal of molecular sciences · 2024
    Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Recent and Ongoing Research into Metastatic Osteosarcoma Treatments.International journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Lu XieMusculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China.
Yufei YangThe Division of Bioinformatics, Genetron Health (Beijing) Co. Ltd., Beijing, China.
Wei GuoMusculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China.
Dongxue CheThe Division of Bioinformatics, Genetron Health (Beijing) Co. Ltd., Beijing, China.
Jie XuMusculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China.
Xin SunMusculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China.
Kuisheng LiuMusculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China.
Tingting RenMusculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China.
Xingyu LiuMusculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China.
Yi YangMusculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China.
Tao JiMusculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China.
Xiaodong TangMusculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China.
Peking University · CNPeking University People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOsteosarcoma (OTS) is aggressive bone malignancy without well-recognized prognosis biomarker. Tumor mutational burden (TMB) has been proved as effective biomarker in predicting clinical outcomes in several cancer types. However, its prognostic value in OTS remains unknown. In this study, we aim to evaluate the implication of TMB in OTS patients.

methodsTo depict the landscape of somatic mutations in OTS, we performed Whole-Exome Sequencing (WES) on 31 OTS tissue samples and corresponding White Blood Cells (WBCs) as matched control. TMB was calculated as the total number of somatic alterations in coding regions normalized to the per sequenced genomic megabase (~30.4Mb in WES). The prognostic values of TMB were evaluated by Kaplan-Meier methods and Cox regression models.

resultsThe median age was 16.0 years at diagnosis, and 54.8% of patients were male. The most common genetic alterations were mainly involved in cell cycle and DNA damage response and repair, including H3F3A, TP53, MYC, and CDKN2A/B. The median progression-free survival (PFS) was 775.5 days in TMB-High (defined as third quartile of TMB value, <2.565) versus 351 days in TMB-Low (<2.565). All patients with TMB-High are PFS-Long (>400 days), while 36.4% of all patients with TMB-Low were PFS-Long (

conclusionsTMB-High can be used as prognostic marker for OTS. Our findings demonstrate that TMB may be helpful in combination with traditionally clinicopathologic risk factors to optimize risk stratification and guide treatment decisions.

Indexed as

osteosarcomaoverall survivalprogression-free survivaltumor mutational burdenwhole-exome sequencing

Identifiers

PMID33898301
PMCPMC8059407
OpenAlexW3151795718

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.